New drug IC14 targets heart inflammation in rare condition
NCT ID NCT06275893
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 30 times
Summary
This early-phase study tested a drug called IC14 in one person with arrhythmogenic cardiomyopathy, a rare heart condition that can cause dangerous rhythms. The goal was to see if the drug is safe and reduces inflammation, which may help control the disease. Participants received four IV doses and were monitored with blood tests, heart scans, and their implanted defibrillator.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.